Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges
Authors:
Open Access
- 17 February 2020
- journal article
- review article
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 70 (3) , 291-301
Abstract
Results from numerous pre-clinical studies suggest that a well known anticonvulsant drug valproic acid (VPA) and other short-chain fatty acids (SCFAs) cause significant inhibition of cancer cell proliferation by modulating multiple signaling pathways. First of all, they act as histone deacetylase (HDAC) inhibitors (HDIs), being involved in the epigenetic regulation of gene expression. Afterward, VPA is shown to induce apoptosis and cell differentiation, as well as regulate Notch signaling. Moreover, it up-regulates the expression of certain G protein-coupled receptors (GPCRs), which are involved in various signaling pathways associated with cancer. As a consequence, some pre-clinical and clinical trials were carried out to estimate anticancer effectiveness of VPA, in monotherapy and in new drug combinations, while other SCFAs were tested in pre-clinical studies. The present manuscript summarizes the most important information from the literature about their potent anticancer activities to show some future perspectives related to epigenetic therapy.Keywords
This publication has 39 references indexed in Scilit:
- Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in breast cancer cell lineJournal of Radiation and Cancer Research, 2018
- Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drugThe Lancet Neurology, 2016
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer AgentsMolecules, 2015
- The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch SignalingJournal of Cancer, 2015
- Could valproic acid be an effective anticancer agent? The evidence so farExpert Review of Anticancer Therapy, 2014
- Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted StrategyMedicinal Research Reviews, 2014
- Histone deacetylase inhibitors – molecular mechanisms of actions and clinical applicationsPostępy Higieny I Medycyny Doświadczalnej, 2013
- Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type IIArchives of Gynecology and Obstetrics, 2013
- Histone deacetylases and epigenetic therapies of hematological malignanciesPharmacological Research, 2010
- Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumorsCancer Treatment Reviews, 2008